APO Research
Talk to an analyst

APO RESEARCH · REPORT

Formulation Development CDMO

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Formulation Development CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

5 June 2026192 pages

Choose your research edition.

Industry ResearchFormulation Development CDMO Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Formulation Development CDMO Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Formulation Development CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Formulation Development CDMO Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Formulation Development CDMO Market Analysis and Forecast 2026-2032242 pages · $4,950 USD

Market perspective

The global Formulation Development CDMO market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Formulation Development CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Formulation Development CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Formulation Development CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Formulation Development CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Formulation Development CDMO include Lonza, Ascendia Pharmaceutical Solutions, Catalent, Cambrex, Serán Bioscience, Singota Solutions, Adragos Pharma, Meribel Pharma and Eurofins CDMO, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Formulation Development CDMO market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Formulation Development CDMO and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Formulation Development CDMO revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Formulation Development CDMO market size, projected growth trends, production technologies, key applications, and end-use industries.

Formulation Development CDMO Segment by Company

Lonza

Ascendia Pharmaceutical Solutions

Catalent

Cambrex

Serán Bioscience

Singota Solutions

Adragos Pharma

Meribel Pharma

Eurofins CDMO

Skyepharma

Siegfried Group

Recipharm

CordenPharma

Thermo Fisher Scientific

Samsung Biologics

AGC Biologics

WuXi AppTec

Pharmaron

Asymchem

Huahai Pharma

Nipro Pharma

CMIC Group

Hovione

Formulation Development CDMO Segment by Type

Oral Solid Dosage Forms

Injectable Dosage Forms

Transdermal Dosage Forms

Others

Formulation Development CDMO Segment by Application

Small molecule chemical drugs

Biologics

Cell and gene therapy products

Others

Formulation Development CDMO Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Formulation Development CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Formulation Development CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Formulation Development CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Formulation Development CDMO in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Formulation Development CDMO industry.

Chapter 3: Detailed analysis of Formulation Development CDMO companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Formulation Development CDMOrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Formulation Development CDMO Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Oral Solid Dosage Forms Table 3. Key Players of Injectable Dosage Forms Table 4. Key Players of Transdermal Dosage Forms Table 3. Key Players of Others Table 4. Global Formulation Development CDMO Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Small molecule chemical drugs Table 6. Key Players of Biologics Table 7. Key Players of Cell and gene therapy products Table 8. Key Players of Others Table 9. Global Formulation Development CDMO Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 10. Global Formulation Development CDMO Market Size by Region (2021-2026) & (US$ Million) Table 11. Global Formulation Development CDMO Market Share by Region (2021-2026) Table 12. Global Formulation Development CDMO Market Size by Region (2027-2032) & (US$ Million) Table 13. Global Formulation Development CDMO Market Share by Region (2027-2032) Table 14. Formulation Development CDMO Industry Trends Table 15. Formulation Development CDMO Industry Drivers Table 16. Formulation Development CDMO Industry Opportunities and Challenges Table 17. Formulation Development CDMO Industry Restraints Table 18. Global Formulation Development CDMO Revenue by Company (US$ Million) & (2021-2026) Table 19. Global Formulation Development CDMO Revenue Market Share by Company (2021-2026) Table 20. Global Formulation Development CDMO Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 21. Global Formulation Development CDMO Key Company Head Office and Area Served Table 22. Global Formulation Development CDMO Company, Product Type & Application Table 23. Global Formulation Development CDMO Company Establishment Date Table 24. Global Company Market Concentration Ratio (CR5 and HHI) Table 25. Global Formulation Development CDMO by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 26. Global Formulation Development CDMO Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Formulation Development CDMO Market Size by Type (2021-2026) & (US$ Million) Table 28. Global Formulation Development CDMO Market Size by Type (2027-2032) & (US$ Million) Table 29. Global Formulation Development CDMO Revenue Market Share by Type (2021-2026) Table 30. Global Formulation Development CDMO Revenue Market Share by Type (2027-2032) Table 31. Global Formulation Development CDMO Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Formulation Development CDMO Market Size by Application (2021-2026) & (US$ Million) Table 33. Global Formulation Development CDMO Market Size by Application (2027-2032) & (US$ Million) Table 34. Global Formulation Development CDMO Revenue Market Share by Application (2021-2026) Table 35. Global Formulation Development CDMO Revenue Market Share by Application (2027-2032) Table 36. Lonza Company Information Table 37. Lonza Business Overview Table 38. Lonza Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Lonza Formulation Development CDMO Product Portfolio Table 40. Lonza Recent Development Table 41. Ascendia Pharmaceutical Solutions Company Information Table 42. Ascendia Pharmaceutical Solutions Business Overview Table 43. Ascendia Pharmaceutical Solutions Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Ascendia Pharmaceutical Solutions Formulation Development CDMO Product Portfolio Table 45. Ascendia Pharmaceutical Solutions Recent Development Table 46. Catalent Company Information Table 47. Catalent Business Overview Table 48. Catalent Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Catalent Formulation Development CDMO Product Portfolio Table 50. Catalent Recent Development Table 51. Cambrex Company Information Table 52. Cambrex Business Overview Table 53. Cambrex Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Cambrex Formulation Development CDMO Product Portfolio Table 55. Cambrex Recent Development Table 56. Serán Bioscience Company Information Table 57. Serán Bioscience Business Overview Table 58. Serán Bioscience Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Serán Bioscience Formulation Development CDMO Product Portfolio Table 60. Serán Bioscience Recent Development Table 61. Singota Solutions Company Information Table 62. Singota Solutions Business Overview Table 63. Singota Solutions Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Singota Solutions Formulation Development CDMO Product Portfolio Table 65. Singota Solutions Recent Development Table 66. Adragos Pharma Company Information Table 67. Adragos Pharma Business Overview Table 68. Adragos Pharma Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Adragos Pharma Formulation Development CDMO Product Portfolio Table 70. Adragos Pharma Recent Development Table 71. Meribel Pharma Company Information Table 72. Meribel Pharma Business Overview Table 73. Meribel Pharma Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Meribel Pharma Formulation Development CDMO Product Portfolio Table 75. Meribel Pharma Recent Development Table 76. Eurofins CDMO Company Information Table 77. Eurofins CDMO Business Overview Table 78. Eurofins CDMO Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Eurofins CDMO Formulation Development CDMO Product Portfolio Table 80. Eurofins CDMO Recent Development Table 81. Skyepharma Company Information Table 82. Skyepharma Business Overview Table 83. Skyepharma Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Skyepharma Formulation Development CDMO Product Portfolio Table 85. Skyepharma Recent Development Table 86. Siegfried Group Company Information Table 87. Siegfried Group Business Overview Table 88. Siegfried Group Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 89. Siegfried Group Formulation Development CDMO Product Portfolio Table 90. Siegfried Group Recent Development Table 91. Recipharm Company Information Table 92. Recipharm Business Overview Table 93. Recipharm Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 94. Recipharm Formulation Development CDMO Product Portfolio Table 95. Recipharm Recent Development Table 96. CordenPharma Company Information Table 97. CordenPharma Business Overview Table 98. CordenPharma Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 99. CordenPharma Formulation Development CDMO Product Portfolio Table 100. CordenPharma Recent Development Table 101. Thermo Fisher Scientific Company Information Table 102. Thermo Fisher Scientific Business Overview Table 103. Thermo Fisher Scientific Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 104. Thermo Fisher Scientific Formulation Development CDMO Product Portfolio Table 105. Thermo Fisher Scientific Recent Development Table 106. Samsung Biologics Company Information Table 107. Samsung Biologics Business Overview Table 108. Samsung Biologics Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 109. Samsung Biologics Formulation Development CDMO Product Portfolio Table 110. Samsung Biologics Recent Development Table 111. AGC Biologics Company Information Table 112. AGC Biologics Business Overview Table 113. AGC Biologics Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 114. AGC Biologics Formulation Development CDMO Product Portfolio Table 115. AGC Biologics Recent Development Table 116. WuXi AppTec Company Information Table 117. WuXi AppTec Business Overview Table 118. WuXi AppTec Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 119. WuXi AppTec Formulation Development CDMO Product Portfolio Table 120. WuXi AppTec Recent Development Table 121. Pharmaron Company Information Table 122. Pharmaron Business Overview Table 123. Pharmaron Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 124. Pharmaron Formulation Development CDMO Product Portfolio Table 125. Pharmaron Recent Development Table 126. Asymchem Company Information Table 127. Asymchem Business Overview Table 128. Asymchem Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 129. Asymchem Formulation Development CDMO Product Portfolio Table 130. Asymchem Recent Development Table 131. Huahai Pharma Company Information Table 132. Huahai Pharma Business Overview Table 133. Huahai Pharma Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 134. Huahai Pharma Formulation Development CDMO Product Portfolio Table 135. Huahai Pharma Recent Development Table 136. Nipro Pharma Company Information Table 137. Nipro Pharma Business Overview Table 138. Nipro Pharma Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 139. Nipro Pharma Formulation Development CDMO Product Portfolio Table 140. Nipro Pharma Recent Development Table 141. CMIC Group Company Information Table 142. CMIC Group Business Overview Table 143. CMIC Group Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 144. CMIC Group Formulation Development CDMO Product Portfolio Table 145. CMIC Group Recent Development Table 146. Hovione Company Information Table 147. Hovione Business Overview Table 148. Hovione Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 149. Hovione Formulation Development CDMO Product Portfolio Table 150. Hovione Recent Development Table 151. North America Formulation Development CDMO Market Size by Type (2021-2026) & (US$ Million) Table 152. North America Formulation Development CDMO Market Size by Type (2027-2032) & (US$ Million) Table 153. North America Formulation Development CDMO Market Size by Application (2021-2026) & (US$ Million) Table 154. North America Formulation Development CDMO Market Size by Application (2027-2032) & (US$ Million) Table 155. North America Formulation Development CDMO Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 156. North America Formulation Development CDMO Market Size by Country (2021-2026) Table 157. North America Formulation Development CDMO Market Size by Country (2027-2032) Table 158. Europe Formulation Development CDMO Market Size by Type (2021-2026) & (US$ Million) Table 159. Europe Formulation Development CDMO Market Size by Type (2027-2032) & (US$ Million) Table 160. Europe Formulation Development CDMO Market Size by Application (2021-2026) & (US$ Million) Table 161. Europe Formulation Development CDMO Market Size by Application (2027-2032) & (US$ Million) Table 162. Europe Formulation Development CDMO Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 163. Europe Formulation Development CDMO Market Size by Country (2021-2026) Table 164. Europe Formulation Development CDMO Market Size by Country (2027-2032) Table 165. China Formulation Development CDMO Market Size by Type (2021-2026) & (US$ Million) Table 166. China Formulation Development CDMO Market Size by Type (2027-2032) & (US$ Million) Table 167. China Formulation Development CDMO Market Size by Application (2021-2026) & (US$ Million) Table 168. China Formulation Development CDMO Market Size by Application (2027-2032) & (US$ Million) Table 169. Asia Formulation Development CDMO Market Size by Type (2021-2026) & (US$ Million) Table 170. Asia Formulation Development CDMO Market Size by Type (2027-2032) & (US$ Million) Table 171. Asia Formulation Development CDMO Market Size by Application (2021-2026) & (US$ Million) Table 172. Asia Formulation Development CDMO Market Size by Application (2027-2032) & (US$ Million) Table 173. Asia Formulation Development CDMO Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 174. Asia Formulation Development CDMO Market Size by Country (2021-2026) Table 175. Asia Formulation Development CDMO Market Size by Country (2027-2032) Table 176. South America, Middle East & Africa Formulation Development CDMO Market Size by Type (2021-2026) & (US$ Million) Table 177. South America, Middle East & Africa Formulation Development CDMO Market Size by Type (2027-2032) & (US$ Million) Table 178. South America, Middle East & Africa Formulation Development CDMO Market Size by Application (2021-2026) & (US$ Million) Table 179. South America, Middle East & Africa Formulation Development CDMO Market Size by Application (2027-2032) & (US$ Million) Table 180. South America, Middle East & Africa Formulation Development CDMO Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 181. South America, Middle East & Africa Formulation Development CDMO Market Size by Country (2021-2026) Table 182. South America, Middle East & Africa Formulation Development CDMO Market Size by Country (2027-2032) Table 183. Research Programs/Design for This Report Table 184. Authors List of This Report Table 185. Secondary Sources Table 186. Primary Sources List of Figures Figure 1. Formulation Development CDMO Product Image Figure 2. Global Formulation Development CDMO Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Formulation Development CDMO Market Share by Type: 2025 VS 2032 Figure 4. Oral Solid Dosage Forms Image Figure 5. Injectable Dosage Forms Image Figure 6. Transdermal Dosage Forms Image Figure 7. Others Image Figure 8. Global Formulation Development CDMO Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 9. Global Formulation Development CDMO Market Share by Application: 2025 VS 2032 Figure 10. Small molecule chemical drugs Image Figure 11. Biologics Image Figure 12. Cell and gene therapy products Image Figure 13. Others Image Figure 14. Global Formulation Development CDMO Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Formulation Development CDMO Market Size (2021-2032) & (US$ Million) Figure 16. Global Formulation Development CDMO Market Share by Region: 2025 VS 2032 Figure 17. Years Considered Figure 18. Global Formulation Development CDMO Market Share by Players in 2025 Figure 19. Global Top 5 and 10 Formulation Development CDMO Players Market Share by Revenue in 2025 Figure 20. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Formulation Development CDMO Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Formulation Development CDMO Revenue Market Share by Type (2021-2032) Figure 23. Global Formulation Development CDMO Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Formulation Development CDMO Revenue Market Share by Application (2021-2032) Figure 25. North America Formulation Development CDMO Market Size (2021-2032) & (US$ Million) Figure 26. North America Formulation Development CDMO Market Share by Type (2021-2032) Figure 27. North America Formulation Development CDMO Market Share by Application (2021-2032) Figure 28. North America Formulation Development CDMO Market Share by Country (2021-2032) Figure 29. United States Formulation Development CDMO Market Size (2021-2032) & (US$ Million) Figure 30. Canada Formulation Development CDMO Market Size (2021-2032) & (US$ Million) Figure 31. Mexico Formulation Development CDMO Market Size (2021-2032) & (US$ Million) Figure 32. Europe Formulation Development CDMO Market Size (2021-2032) & (US$ Million) Figure 33. Europe Formulation Development CDMO Market Share by Type (2021-2032) Figure 34. Europe Formulation Development CDMO Market Share by Application (2021-2032) Figure 35. Europe Formulation Development CDMO Market Share by Country (2021-2032) Figure 36. Germany Formulation Development CDMO Market Size (2021-2032) & (US$ Million) Figure 37. France Formulation Development CDMO Market Size (2021-2032) & (US$ Million) Figure 38. U.K. Formulation Development CDMO Market Size (2021-2032) & (US$ Million) Figure 39. Italy Formulation Development CDMO Market Size (2021-2032) & (US$ Million) Figure 40. Russia Formulation Development CDMO Market Size (2021-2032) & (US$ Million) Figure 41. Nordic Countries Formulation Development CDMO Market Size (2021-2032) & (US$ Million) Figure 42. China Formulation Development CDMO Market Size (2021-2032) & (US$ Million) Figure 43. China Formulation Development CDMO Market Share by Type (2021-2032) Figure 44. China Formulation Development CDMO Market Share by Application (2021-2032) Figure 45. Asia Formulation Development CDMO Market Size (2021-2032) & (US$ Million) Figure 46. Asia Formulation Development CDMO Market Share by Type (2021-2032) Figure 47. Asia Formulation Development CDMO Market Share by Application (2021-2032) Figure 48. Asia Formulation Development CDMO Market Share by Country (2021-2032) Figure 49. Japan Formulation Development CDMO Market Size (2021-2032) & (US$ Million) Figure 50. South Korea Formulation Development CDMO Market Size (2021-2032) & (US$ Million) Figure 51. Taiwan Formulation Development CDMO Market Size (2021-2032) & (US$ Million) Figure 52. Southeast Asia Formulation Development CDMO Market Size (2021-2032) & (US$ Million) Figure 53. India Formulation Development CDMO Market Size (2021-2032) & (US$ Million) Figure 54. Australia Formulation Development CDMO Market Size (2021-2032) & (US$ Million) Figure 55. South America, Middle East & Africa Formulation Development CDMO Market Size (2021-2032) & (US$ Million) Figure 56. South America, Middle East & Africa Formulation Development CDMO Market Share by Type (2021-2032) Figure 57. South America, Middle East & Africa Formulation Development CDMO Market Share by Application (2021-2032) Figure 58. South America, Middle East & Africa Formulation Development CDMO Market Share by Country (2021-2032) Figure 59. Brazil Formulation Development CDMO Market Size (2021-2032) & (US$ Million) Figure 60. South Africa Formulation Development CDMO Market Size (2021-2032) & (US$ Million) Figure 61. Saudi Arabia Formulation Development CDMO Market Size (2021-2032) & (US$ Million) Figure 62. Turkey Formulation Development CDMO Market Size (2021-2032) & (US$ Million) Figure 63. Argentina Formulation Development CDMO Market Size (2021-2032) & (US$ Million) Figure 64. UAE Formulation Development CDMO Market Size (2021-2032) & (US$ Million) Figure 65. Egypt Formulation Development CDMO Market Size (2021-2032) & (US$ Million) Figure 66. Chile Formulation Development CDMO Market Size (2021-2032) & (US$ Million) Figure 67. Research Process Figure 68. Key Executives Interviewed

Scope & coverage.

Types
  • Oral Solid Dosage Forms
  • Injectable Dosage Forms
  • Transdermal Dosage Forms
  • Others
Applications
  • Small molecule chemical drugs
  • Biologics
  • Cell and gene therapy products
  • Others
Companies covered
  • Lonza
  • Ascendia Pharmaceutical Solutions
  • Catalent
  • Cambrex
  • Serán Bioscience
  • Singota Solutions
  • Adragos Pharma
  • Meribel Pharma
  • Eurofins CDMO
  • Skyepharma
  • Siegfried Group
  • Recipharm
  • CordenPharma
  • Thermo Fisher Scientific
  • Samsung Biologics
  • AGC Biologics
  • WuXi AppTec
  • Pharmaron
  • Asymchem
  • Huahai Pharma
  • Nipro Pharma
  • CMIC Group
  • Hovione

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Formulation Development CDMO Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Oral Solid Dosage Forms
  5. 1.2.3 Injectable Dosage Forms
  6. 1.2.4 Transdermal Dosage Forms
  7. 1.2.5 Others
  8. 1.3 Market Analysis by Application
  9. 1.3.1 Global Formulation Development CDMO Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  10. 1.3.2 Small molecule chemical drugs
  11. 1.3.3 Biologics
  12. 1.3.4 Cell and gene therapy products
  13. 1.3.5 Others
  14. 1.4 Global Market Growth Prospects
  15. 1.5 Global Formulation Development CDMO Growth Trends by Region
  16. 1.5.1 Global Formulation Development CDMO Market Size by Region: 2021 VS 2025 VS 2032
  17. 1.5.2 Formulation Development CDMO Market Size by Region (2021-2026)
  18. 1.5.3 Formulation Development CDMO Market Size by Region (2027-2032)
  19. 1.6 Assumptions and Limitations
  20. 1.7 Study Goals and Objectives
  21. 1.8 Years Considered
2 Global Formulation Development CDMO Market Dynamics
  1. 2.1 Formulation Development CDMO Industry Trends
  2. 2.2 Formulation Development CDMO Industry Drivers
  3. 2.3 Formulation Development CDMO Industry Opportunities and Challenges
  4. 2.4 Formulation Development CDMO Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Formulation Development CDMO Revenue by Company (2021-2026)
  2. 3.2 Global Formulation Development CDMO Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Formulation Development CDMO Key Company Head office and Area Served
  4. 3.4 Global Formulation Development CDMO Company, Product Type & Application
  5. 3.5 Global Formulation Development CDMO Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Formulation Development CDMO Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Formulation Development CDMO Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Formulation Development CDMO Tier 1, Tier 2, and Tier 3
4 Formulation Development CDMO Market by Type
  1. 4.1 Global Formulation Development CDMO Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Formulation Development CDMO Market Size by Type (2021-2032)
  3. 4.3 Global Formulation Development CDMO Market Size Share by Type (2021-2032)
5 Formulation Development CDMO Market by Application
  1. 5.1 Global Formulation Development CDMO Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Formulation Development CDMO Market Size by Application (2021-2032)
  3. 5.3 Global Formulation Development CDMO Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Lonza
  2. 6.1.1 Lonza Company Information
  3. 6.1.2 Lonza Business Overview
  4. 6.1.3 Lonza Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Lonza Formulation Development CDMO Product Portfolio
  6. 6.1.5 Lonza Recent Developments
  7. 6.2 Ascendia Pharmaceutical Solutions
  8. 6.2.1 Ascendia Pharmaceutical Solutions Company Information
  9. 6.2.2 Ascendia Pharmaceutical Solutions Business Overview
  10. 6.2.3 Ascendia Pharmaceutical Solutions Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Ascendia Pharmaceutical Solutions Formulation Development CDMO Product Portfolio
  12. 6.2.5 Ascendia Pharmaceutical Solutions Recent Developments
  13. 6.3 Catalent
  14. 6.3.1 Catalent Company Information
  15. 6.3.2 Catalent Business Overview
  16. 6.3.3 Catalent Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Catalent Formulation Development CDMO Product Portfolio
  18. 6.3.5 Catalent Recent Developments
  19. 6.4 Cambrex
  20. 6.4.1 Cambrex Company Information
  21. 6.4.2 Cambrex Business Overview
  22. 6.4.3 Cambrex Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Cambrex Formulation Development CDMO Product Portfolio
  24. 6.4.5 Cambrex Recent Developments
  25. 6.5 Serán Bioscience
  26. 6.5.1 Serán Bioscience Company Information
  27. 6.5.2 Serán Bioscience Business Overview
  28. 6.5.3 Serán Bioscience Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Serán Bioscience Formulation Development CDMO Product Portfolio
  30. 6.5.5 Serán Bioscience Recent Developments
  31. 6.6 Singota Solutions
  32. 6.6.1 Singota Solutions Company Information
  33. 6.6.2 Singota Solutions Business Overview
  34. 6.6.3 Singota Solutions Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Singota Solutions Formulation Development CDMO Product Portfolio
  36. 6.6.5 Singota Solutions Recent Developments
  37. 6.7 Adragos Pharma
  38. 6.7.1 Adragos Pharma Company Information
  39. 6.7.2 Adragos Pharma Business Overview
  40. 6.7.3 Adragos Pharma Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Adragos Pharma Formulation Development CDMO Product Portfolio
  42. 6.7.5 Adragos Pharma Recent Developments
  43. 6.8 Meribel Pharma
  44. 6.8.1 Meribel Pharma Company Information
  45. 6.8.2 Meribel Pharma Business Overview
  46. 6.8.3 Meribel Pharma Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Meribel Pharma Formulation Development CDMO Product Portfolio
  48. 6.8.5 Meribel Pharma Recent Developments
  49. 6.9 Eurofins CDMO
  50. 6.9.1 Eurofins CDMO Company Information
  51. 6.9.2 Eurofins CDMO Business Overview
  52. 6.9.3 Eurofins CDMO Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Eurofins CDMO Formulation Development CDMO Product Portfolio
  54. 6.9.5 Eurofins CDMO Recent Developments
  55. 6.10 Skyepharma
  56. 6.10.1 Skyepharma Company Information
  57. 6.10.2 Skyepharma Business Overview
  58. 6.10.3 Skyepharma Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Skyepharma Formulation Development CDMO Product Portfolio
  60. 6.10.5 Skyepharma Recent Developments
  61. 6.11 Siegfried Group
  62. 6.11.1 Siegfried Group Company Information
  63. 6.11.2 Siegfried Group Business Overview
  64. 6.11.3 Siegfried Group Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Siegfried Group Formulation Development CDMO Product Portfolio
  66. 6.11.5 Siegfried Group Recent Developments
  67. 6.12 Recipharm
  68. 6.12.1 Recipharm Company Information
  69. 6.12.2 Recipharm Business Overview
  70. 6.12.3 Recipharm Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 Recipharm Formulation Development CDMO Product Portfolio
  72. 6.12.5 Recipharm Recent Developments
  73. 6.13 CordenPharma
  74. 6.13.1 CordenPharma Company Information
  75. 6.13.2 CordenPharma Business Overview
  76. 6.13.3 CordenPharma Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 CordenPharma Formulation Development CDMO Product Portfolio
  78. 6.13.5 CordenPharma Recent Developments
  79. 6.14 Thermo Fisher Scientific
  80. 6.14.1 Thermo Fisher Scientific Company Information
  81. 6.14.2 Thermo Fisher Scientific Business Overview
  82. 6.14.3 Thermo Fisher Scientific Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  83. 6.14.4 Thermo Fisher Scientific Formulation Development CDMO Product Portfolio
  84. 6.14.5 Thermo Fisher Scientific Recent Developments
  85. 6.15 Samsung Biologics
  86. 6.15.1 Samsung Biologics Company Information
  87. 6.15.2 Samsung Biologics Business Overview
  88. 6.15.3 Samsung Biologics Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  89. 6.15.4 Samsung Biologics Formulation Development CDMO Product Portfolio
  90. 6.15.5 Samsung Biologics Recent Developments
  91. 6.16 AGC Biologics
  92. 6.16.1 AGC Biologics Company Information
  93. 6.16.2 AGC Biologics Business Overview
  94. 6.16.3 AGC Biologics Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  95. 6.16.4 AGC Biologics Formulation Development CDMO Product Portfolio
  96. 6.16.5 AGC Biologics Recent Developments
  97. 6.17 WuXi AppTec
  98. 6.17.1 WuXi AppTec Company Information
  99. 6.17.2 WuXi AppTec Business Overview
  100. 6.17.3 WuXi AppTec Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  101. 6.17.4 WuXi AppTec Formulation Development CDMO Product Portfolio
  102. 6.17.5 WuXi AppTec Recent Developments
  103. 6.18 Pharmaron
  104. 6.18.1 Pharmaron Company Information
  105. 6.18.2 Pharmaron Business Overview
  106. 6.18.3 Pharmaron Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  107. 6.18.4 Pharmaron Formulation Development CDMO Product Portfolio
  108. 6.18.5 Pharmaron Recent Developments
  109. 6.19 Asymchem
  110. 6.19.1 Asymchem Company Information
  111. 6.19.2 Asymchem Business Overview
  112. 6.19.3 Asymchem Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  113. 6.19.4 Asymchem Formulation Development CDMO Product Portfolio
  114. 6.19.5 Asymchem Recent Developments
  115. 6.20 Huahai Pharma
  116. 6.20.1 Huahai Pharma Company Information
  117. 6.20.2 Huahai Pharma Business Overview
  118. 6.20.3 Huahai Pharma Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  119. 6.20.4 Huahai Pharma Formulation Development CDMO Product Portfolio
  120. 6.20.5 Huahai Pharma Recent Developments
  121. 6.21 Nipro Pharma
  122. 6.21.1 Nipro Pharma Company Information
  123. 6.21.2 Nipro Pharma Business Overview
  124. 6.21.3 Nipro Pharma Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  125. 6.21.4 Nipro Pharma Formulation Development CDMO Product Portfolio
  126. 6.21.5 Nipro Pharma Recent Developments
  127. 6.22 CMIC Group
  128. 6.22.1 CMIC Group Company Information
  129. 6.22.2 CMIC Group Business Overview
  130. 6.22.3 CMIC Group Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  131. 6.22.4 CMIC Group Formulation Development CDMO Product Portfolio
  132. 6.22.5 CMIC Group Recent Developments
  133. 6.23 Hovione
  134. 6.23.1 Hovione Company Information
  135. 6.23.2 Hovione Business Overview
  136. 6.23.3 Hovione Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026)
  137. 6.23.4 Hovione Formulation Development CDMO Product Portfolio
  138. 6.23.5 Hovione Recent Developments
7 North America
  1. 7.1 North America Formulation Development CDMO Market Size (2021-2032)
  2. 7.2 North America Formulation Development CDMO Market Size by Type
  3. 7.2.1 North America Formulation Development CDMO Market Size by Type (2021-2026)
  4. 7.2.2 North America Formulation Development CDMO Market Size by Type (2027-2032)
  5. 7.2.3 North America Formulation Development CDMO Market Share by Type (2021-2032)
  6. 7.3 North America Formulation Development CDMO Market Size by Application
  7. 7.3.1 North America Formulation Development CDMO Market Size by Application (2021-2026)
  8. 7.3.2 North America Formulation Development CDMO Market Size by Application (2027-2032)
  9. 7.3.3 North America Formulation Development CDMO Market Share by Application (2021-2032)
  10. 7.4 North America Formulation Development CDMO Market Size by Country
  11. 7.4.1 North America Formulation Development CDMO Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Formulation Development CDMO Market Size by Country (2021-2026)
  13. 7.4.3 North America Formulation Development CDMO Market Size by Country (2027-2032)
  14. 7.4.4 North America Formulation Development CDMO Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Formulation Development CDMO Market Size (2021-2032)
  2. 8.2 Europe Formulation Development CDMO Market Size by Type
  3. 8.2.1 Europe Formulation Development CDMO Market Size by Type (2021-2026)
  4. 8.2.2 Europe Formulation Development CDMO Market Size by Type (2027-2032)
  5. 8.2.3 Europe Formulation Development CDMO Market Share by Type (2021-2032)
  6. 8.3 Europe Formulation Development CDMO Market Size by Application
  7. 8.3.1 Europe Formulation Development CDMO Market Size by Application (2021-2026)
  8. 8.3.2 Europe Formulation Development CDMO Market Size by Application (2027-2032)
  9. 8.3.3 Europe Formulation Development CDMO Market Share by Application (2021-2032)
  10. 8.4 Europe Formulation Development CDMO Market Size by Country
  11. 8.4.1 Europe Formulation Development CDMO Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Formulation Development CDMO Market Size by Country (2021-2026)
  13. 8.4.3 Europe Formulation Development CDMO Market Size by Country (2027-2032)
  14. 8.4.4 Europe Formulation Development CDMO Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Formulation Development CDMO Market Size (2021-2032)
  2. 9.2 China Formulation Development CDMO Market Size by Type
  3. 9.2.1 China Formulation Development CDMO Market Size by Type (2021-2026)
  4. 9.2.2 China Formulation Development CDMO Market Size by Type (2027-2032)
  5. 9.2.3 China Formulation Development CDMO Market Share by Type (2021-2032)
  6. 9.3 China Formulation Development CDMO Market Size by Application
  7. 9.3.1 China Formulation Development CDMO Market Size by Application (2021-2026)
  8. 9.3.2 China Formulation Development CDMO Market Size by Application (2027-2032)
  9. 9.3.3 China Formulation Development CDMO Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Formulation Development CDMO Market Size (2021-2032)
  2. 10.2 Asia Formulation Development CDMO Market Size by Type
  3. 10.2.1 Asia Formulation Development CDMO Market Size by Type (2021-2026)
  4. 10.2.2 Asia Formulation Development CDMO Market Size by Type (2027-2032)
  5. 10.2.3 Asia Formulation Development CDMO Market Share by Type (2021-2032)
  6. 10.3 Asia Formulation Development CDMO Market Size by Application
  7. 10.3.1 Asia Formulation Development CDMO Market Size by Application (2021-2026)
  8. 10.3.2 Asia Formulation Development CDMO Market Size by Application (2027-2032)
  9. 10.3.3 Asia Formulation Development CDMO Market Share by Application (2021-2032)
  10. 10.4 Asia Formulation Development CDMO Market Size by Country
  11. 10.4.1 Asia Formulation Development CDMO Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Formulation Development CDMO Market Size by Country (2021-2026)
  13. 10.4.3 Asia Formulation Development CDMO Market Size by Country (2027-2032)
  14. 10.4.4 Asia Formulation Development CDMO Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Formulation Development CDMO Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Formulation Development CDMO Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Formulation Development CDMO Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Formulation Development CDMO Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Formulation Development CDMO Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Formulation Development CDMO Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Formulation Development CDMO Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Formulation Development CDMO Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Formulation Development CDMO Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Formulation Development CDMO Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Formulation Development CDMO Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Formulation Development CDMO Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Formulation Development CDMO Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Formulation Development CDMO Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst